Literature DB >> 9710043

Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy.

M Mirabella1, G Galluzzi, G Manfredi, E Bertini, E Ricci, R De Leo, P Tonali, S Servidei.   

Abstract

We report a patient with a large intragenic dystrophin deletion of exons 17-51 inclusive associated with congenital cataract and mild Becker muscular dystrophy. The cataract was similar to the congenital cataract described in the mdx mouse. The loss of 68% of the rod domain including hinge 2 and 3 regions did not adversely affect the correct localization of the dystrophin and the association with the dystrophin-associated glycoprotein complex. This observation may have implications for minigenes suitable for gene therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710043     DOI: 10.1212/wnl.51.2.592

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.

Authors:  B Wang; J Li; X Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Authors:  Sarah Forrest; Penny L Meloni; Francesco Muntoni; Jihee Kim; Sue Fletcher; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

3.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Authors:  Annemieke Aartsma-Rus; Anneke A M Janson; Wendy E Kaman; Mattie Bremmer-Bout; Gert-Jan B van Ommen; Johan T den Dunnen; Judith C T van Deutekom
Journal:  Am J Hum Genet       Date:  2003-12-16       Impact factor: 11.025

4.  Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice.

Authors:  Bo Wu; Yongfu Li; Paul A Morcos; Timothy J Doran; Peijuan Lu; Qi Long Lu
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

Review 5.  Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.

Authors:  Anthony Scimè; Michael A Rudnicki
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 6.  Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

7.  Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther Clin Dev       Date:  2016-03       Impact factor: 5.032

8.  Multiple exon skipping strategies to by-pass dystrophin mutations.

Authors:  Carl F Adkin; Penelope L Meloni; Susan Fletcher; Abbie M Adams; Francesco Muntoni; Brenda Wong; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2011-12-17       Impact factor: 4.296

9.  Utility of MLPA in mutation analysis and carrier detection for Duchenne muscular dystrophy.

Authors:  Prashant K Verma; Ashwin Dalal; Balraj Mittal; Shubha R Phadke
Journal:  Indian J Hum Genet       Date:  2012-01

10.  Biochemical and biomechanical characteristics of dystrophin-deficient mdx3cv mouse lens.

Authors:  Shruthi Karnam; Nikolai P Skiba; Ponugoti V Rao
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-10-27       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.